MAYO CLINIC LABORATORIES

1-800-533-1710

# MRDMM

Multiple Myeloma Minimal Residual Disease by Flow, Bone Marrow

| Patient ID | Patient Name | | Birth Date | Sex | Age |
|---|---|---|---|---|---|
| SA00155798 | TESTINGRNV, MRDMM | | 1995-04-15 | F | 27 |
| **Order Number** | **Client Order Number** | **Ordering Physician** | **Report Notes** | | |
| SA00155798 | SA00155798 | CLIENT,CLIENT | | | |
| **Account Information** | | **Collected** | | | |
| C7028846 DLMP Rochester | | 12 Dec 2022 07:00 | | | |

## Multiple Myeloma MRD by Flow, BM

### Final Diagnosis

1 MCR

Bone marrow, flow cytometric immunophenotyping:
No monotypic plasma cells identified (MRD-negative).

Reviewed by: SHANDA VOELTZ

### ASSAY DESCRIPTION, METHOD AND LIMITATIONS

This assay is intended for post-therapeutic assessment of patients with plasma cell neoplasms, when in complete remission. Specimens with low cellularity and specimens from patients treated with therapeutic antibodies may interfere with this assay's sensitivity. Based on current literature guidelines, specimens with mast cells <0.002% and B-cell precursors <0.05% of non-aggregated events may suggest hemodilution (PMID: 28104919). Specimens with >5% plasma cells may show false-negative staining due to antigen excess, and plasma cells may not be accurately identified. Correlation with clinical and other laboratory studies is recommended.

Plasma cell analysis was performed with antibodies to the following antigens: Myeloma MRD panel: CD138, CD27, CD38, CD56, CD45, CD19, CD117, CD81, kappa and lambda cytoplasmic immunoglobulin light chains.

Quality Assessment: Specimen received within validated guidelines.

### % Minimal Residual Disease (MRD) — MCR

0.0000 %

### % Normal Plasma Cells (of total PC) — MCR

100.0 %

### Non-Aggregate Events — MCR

9043088

### Total Plasma Cell Events — MCR

640

### Poly PC Events — MCR

640

### Abnormal PC Events — MCR

0

### % B-cell Precursors — MCR

0.023 %

### % Mast Cells — MCR

0.001 %

### Validated Assay Sensitivity — MCR

1.0 x10(-5)



**Performing Site Legend**

| Code | Laboratory | Address | Lab Director | CLIA Certificate |
|---|---|---|---|---|
| MCR | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292 |

| Patient ID | Patient Name | | Birth Date | Sex | Age |
|---|---|---|---|---|---|
| SA00155798 | TESTINGRNV, MRDMM | | 1995-04-15 | F | 27 |
| **Order Number** | **Client Order Number** | **Ordering Physician** | **Report Notes** | | |
| SA00155798 | SA00155798 | CLIENT,CLIENT | | | |
| **Account Information** | | **Collected** | | | |
| C7028846 DLMP Rochester | | 12 Dec 2022 07:00 | | | |

**Lower Limit of Quantitation (LLOQ)** MCR

2.0 x10(-6)

LLOQ is defined as a minimum of 20 abnormal PC events detected in 10 million non-aggregate events, based on literature and internal validation data.

**Patient / Sample Theoretical LOQ** MCR

2.21 x10(-6)

LOQ is calculated as a minimum of 20 abnormal PC events divided by the actual number of non-aggregate events collected for this sample.

**Received:** 12 Dec 2022 13:30 **Reported:** 12 Dec 2022 15:05



## Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**Performing Site Legend**

| Code | Laboratory | Address | Lab Director | CLIA Certificate |
|---|---|---|---|---|
| MCR | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292 |